Ask about this productRelated genes to: CD80 antibody
- Gene:
- CD80 NIH gene
- Name:
- CD80 molecule
- Previous symbol:
- CD28LG, CD28LG1
- Synonyms:
- B7.1, B7-1
- Chromosome:
- 3q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-14
- Date modifiied:
- 2016-10-05
Related products to: CD80 antibody
Related articles to: CD80 antibody
- Porcine epidemic diarrhea (PED) is a highly lethal and airborne disease in neonatal piglets that has caused significant economic losses in the pig industry over the last three decades. Despite the widespread implementation of commercial vaccines, the disease continues to exhibit recurrent outbreaks, primarily owing to suboptimal immunization efficacy. In this study, we engineered recombinant LP12:PEDV tS1, which expresses the truncated S1 domain of the porcine epidemic diarrhea virus (PEDV) spike protein through a surface anchoring mechanism. The expression was confirmed using western blotting, flow cytometry, and indirect immunofluorescence assays, with a maximum protein yield of 1.7657 μg per 1 × 10 CFU. Furthermore, we immunized mice and pigs nasally with LP12:PEDV tS1 separately. Immunization elicited robust mucosal immune responses, as evidenced by a significant increase in specific secretory IgA (sIgA) with neutralizing activity in alveolar lavage fluid and fecal samples. Our results also indicated that LP12:PEDV tS1 activated dendritic cells in the mesenteric lymph nodes of mice, marked by notable upregulation of CD80 and CD86. Successive immunization with LP12:PEDV tS1 protected piglets from PEDV infection and elicited comparable mucosal immune responses across species, demonstrating its strong potential as a PEDV vaccine candidate. Moreover, an intranasal immunization strategy based on recombinant demonstrated suitability for cross-species vaccination between mice and piglets, potentially streamlining the preclinical evaluation process.IMPORTANCEPorcine epidemic diarrhea (PED) is a major cause of piglet mortality. Current control relies on vaccinating pregnant sows with inactivated or attenuated viruses. However, not all sows develop sufficient antibodies to protect piglets. Once piglets are infected, no effective emergency vaccines are available for them, as existing options pose biosafety risks. To address this, we developed a subunit mucosal vaccine using recombinant . This vaccine is cost-effective, enables cross-species immunization, and remarkably provides immediate immunity to prevent viral infection in neonatal piglets. - Source: PubMed
Publication date: 2026/05/11
Hao JiayiZhou XieshenZhang GuoqingDeng LingcongLi LetianWang Maopeng - Macrophage polarization into M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotypes is essential for immune responses and tissue homeostasis. While transcriptional and post-transcriptional mechanisms controlling this process have been characterized, the contribution of alternative mRNA polyadenylation (APA) to polarization requires clarification. Using human monocytic cell lines, we demonstrate that CFIm25, a key APA regulator, controls macrophage polarization states. CFIm25 overexpression enhances M1 characteristics, including nitric oxide production, CD80 expression, pro-inflammatory cytokine secretion, phagocytosis, migration, and cancer cell killing, while suppressing M2 traits. CFIm25 knockdown produces opposite effects. Mechanistically, CFIm25 promotes the proximal polyadenylation of AKT2 mRNA, generating shorter transcripts with enhanced stability and translational efficiency that increase Akt2 protein levels and amplify NF-κB signaling. Blocking the proximal site with antisense oligonucleotides reduces Akt2 expression and induces M2-like phenotypes. These findings establish APA as a critical regulator of macrophage polarization and identify the CFIm25-Akt2-NF-κB axis as a potential therapeutic target for modulating immune responses. - Source: PubMed
Publication date: 2026/04/20
Mukherjee SrimoyeeBarua AtishNaseri MarziehMoore Claire L - Renal carcinoma remains a highly lethal malignancy, and tumor vaccine efficacy is frequently hampered by a profoundly immunosuppressive tumor microenvironment. V-domain Ig suppressor of T-cell activation (VISTA), an inhibitory immune checkpoint enriched in myeloid cells and regulatory T cells (Tregs), represents a critical barrier to effective antitumor immunity. Targeting VISTA may therefore provide a promising strategy to overcome immune suppression and enhance tumor vaccine efficacy. - Source: PubMed
Publication date: 2026/05/08
Wang JiaweiWang ZhenzhenZhao WantingChen HaominLu BowenShao YingxiangZheng YanyanLiu ShanshanWang MengFang LinLi HuizhongNeeli PraveenTian HuiWang GangChai Dafei - Prostate-specific membrane antigen (PSMA)-based vaccination represents a promising immunotherapeutic strategy for prostate cancer; however, its efficacy remains constrained by tumor-induced immune evasion and insufficient activation of antigen-presenting cells. Galectin-9 (LGALS9), an immunoregulatory lectin that contributes to immune suppression, is therefore an attractive target for overcoming tumor-induced immune tolerance. - Source: PubMed
Publication date: 2026/05/08
Lu BowenLiu NingZhao WantingChen HaominShao YingxiangLu HaosenLiu ShanshanYang JieZheng YanyanDing JiageChai DafeiMao Lijun - Intradermal delivery of the Toll-like receptor (TLR)-9 agonist agatolimod/CPG7909, prior to sentinel lymph node (SLN) biopsy was previously shown to induce locoregional and systemic immunity, reduce tumor-involved SLN rates, and improve recurrence-free survival in patients with early-stage melanoma. Remarkably, men exhibited superior dendritic cell (DC) maturation. Here, we report on further sex-based differences in the immune response after intradermal administration of CPG7909, which included higher CD80/CD83 expression levels in conventional (c) DC subsets in men's as compared to women's SLN, as well as higher release levels of IL-1β, TNF, and IL-6 (all contributors to cDC activation) and Th1/Th2 cytokines. In an effort to identify a more effective DC-activating therapy for women, we compared the in-vitro effects of CPG7909 with those of the TLR7/8 agonist resiquimod/R848 on SLN single cells from female patients. R848 induced superior cDC subset activation and TNF, IL-6, IL-10, IL-12, IFNγ, and CXCL10 release. Correlation analyses suggested that IFNα, TNF, and IL-6 were key for CPG7909-induced LNR-cDC activation, whereas R848's effect appeared more cytokine-independent. We conclude that combining locally delivered CPG7909 and R848 in early-stage melanoma will ensure full-range DC subset activation and robust pro-inflammatory T-cell responses in melanoma SLN, independent of sex. - Source: PubMed
Publication date: 2026/05/07
Notohardjo Jessica C LToffoli Elisa CMuijlwijk Taravan den Hout Mari F C MKandiah VinithaLabots Mariettevan de Ven Rienekevan den Eertwegh Alfons J Mde Gruijl Tanja D